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Drug-associated interstitial lung disease (ILD) is not uncommon, with diverse patterns ranging from benign infiltrates to the potentially
fatal acute respiratory distress syndrome. As acute respiratory failure due to drug-associated ILD has an unpredictable onset and rapid
time course, establishing a diagnosis is often difficult. An accurate diagnosis is based on clinical, radiological (including high-resolution
computed tomography) and histological manifestations, although is often only possible by exclusion. Cancer chemotherapy is
commonly associated with acute disease that, on pathology, is often diffuse alveolar damage. Furthermore, a combination of drugs
with or without radiotherapy can increase the risk of ILD. This article reviews treatments for non-small-cell lung cancer (NSCLC) that
are associated with the development of ILD and how systematic evaluation of the possible role of these drugs in ILD is warranted. A
difference between Japan and the rest of the world in reporting rates of ILD when gefitinib (‘Iressa’) has been used in advanced
NSCLC is also discussed. However, the difference remains unexplained, leaving important epidemiological and mechanistic questions.
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HISTORY AND CLASSIFICATION OF DRUG-
ASSOCIATED INTERSTITIAL LUNG DISEASE (ILD)
Drug-associated lung disease is common, with infiltrative lung
disease comprising 70% of cases. Recent experiences of the
approval and introduction of the novel cancer therapy gefitinib
(‘Iressa’) for the treatment of advanced non-small-cell lung cancer
(NSCLC) have indicated international differences of occurrence of
ILD. The frequency of ILD-type events in Japanese patients (1.9%)
appears to be higher than in the rest of the world (0.3%). This
observation has highlighted the need for greater understanding of
the characteristics of drug-associated ILD. Here, we describe the
usual forms of drug-associated ILD and methods of diagnosis and
pathology. The experience of ILD in Japanese patients treated with
gefitinib is illustrated in detail and includes four detailed case
reports to aid recognition.
There are many patterns of drug-associated ILD, ranging from
benign infiltrates to life-threatening acute respiratory distress
syndrome (Camus et al, 2001) (Table 1). These clinical patterns
differ depending on the patient’s illness and drug factors,
including the type of drug. Hence, an increasing number of drugs
are being recognised as being capable of inducing ILD (Foucher
et al, 2003). Classification of drug-associated ILD is still emerging
and is based on clinical, radiological and histological manifesta-
tions. The categories include acute-onset ILD with dense
pulmonary infiltrates leading to acute respiratory failure, ‘classic’
ILD, lobar consolidation, migratory pulmonary opacities and lung
nodules.
Interstitial lung disease is difficult to diagnose. Clinical,
radiological and pathological observations are necessary to exclude
other conditions with similar symptoms, such as lymphangitis
carcinomatosis, pneumonia, allergy, cardiogenic oedema and
pulmonary haemorrhage (Merad et al, 1997). Identification of
drug-associated ILD is further hampered, as clinical imaging and
pathological patterns are not diagnostically reliable; indeed, one
study of high-resolution computed tomography (HRCT) and
histopathology showed that pathological pattern and imaging did
not correspond in 440% of cases (Cleverley et al, 2002). A detailed
recent drug history is essential in making the diagnosis, but there
are important caveats: the rate of onset of the disease may be acute
or delayed, and multiple therapies may obscure the responsible
therapy’s role, while long-term lung-retention of the drug may
impair resolution on discontinuation of the drug. A standard of
drug-associated disease is the use of re-exposure or rechallenge to
confirm diagnosis. However, there is a natural reluctance to put
the patient at risk of further illness, particularly if the drug-
associated disease is severe. Furthermore, the patient may have
comorbid disease that modifies the progression or resolution of
drug-associated illness.
The most common histopathological patterns of drug-associated
lung injury include pulmonary oedema, diffuse alveolar damage
(DAD), nonspecific interstitial pneumonia, bronchiolitis obliterans
organising pneumonia (BOOP), eosinophilic pneumonia (EP) and
pulmonary haemorrhage. Drugs can be associated with several
concurrent pathological patterns. While HRCT may allow predic-
tion of the pathological pattern for ILD in general, this is not the
case for drug-associated ILD. Several recent review articles (Ellis
et al, 2000; Aviram et al, 2001; Cleverley et al, 2002; Erasmus et al,
2002) comprehensively illustrate this point.
Illustrations of drug-associated ILD with acute respiratory
failure
Several patterns of ILD with acute respiratory failure have been
observed (Table 1). Acute respiratory failure due to drug-
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‘Methotrexate lung’ can occur when methotrexate is used to
treat rheumatoid arthritis or cancer. The pattern is similar to the
acute forms of lung disease seen with other drugs. Lymphocytes
are observed in the bronchioalveolar lavage (BAL) fluid and lung
biopsy reveals inflammatory cell interstitial infiltrates and often
demonstrates features of hypersensitivity (Figure 1A) (Imokawa
et al, 2000). Chest radiography usually reveals diffuse interstitial or
mixed interstitial and alveolar infiltrates (Imokawa et al, 2000).
Antibiotic agents such as minocycline, a semisynthetic tetra-
cycline used in the treatment of acne, can cause acute ILD leading
to acute respiratory failure due to acute EP (Oddo et al, 2003).
Eosinophilic pneumonia is essentially diagnosed by increased
number of eosinophils in the BAL (Figure 1B) and is often
associated with a blood sample eosinophilia; lung biopsy should be
avoided. High-resolution computed tomography scans show
patchy consolidation with centrilobular opacities.
Most chemotherapeutic agents can cause ‘chemotherapy lung’,
acute ILD with the pathological features of DAD. Incidence is
estimated at 10%, although it is difficult to obtain accurate
estimates due to the complexities of diagnosis and the small
patient numbers involved. The risk increases with dose and there
may be potentiation by high oxygen and concurrent use of
granulocyte colony-stimulating factor. Diffuse alveolar damage is
characterised histologically by the presence of alveolar airspace
and interstitial oedema, hyaline membrane formation and
proliferation of type II pneumocytes. Radiographs show bilateral
patchy or homogenous airspace consolidation involving mainly
the middle and lower lung zones. High-resolution computed
tomography scans demonstrate extensive bilateral ground-glass
opacities and areas of airspace consolidation (Akira et al, 2002).
In some instances, ILD leading to acute respiratory failure can
occur due to pulmonary oedema as a consequence of permeability
leakage in the alveoli. Alveolar haemorrhage by haemorrhage or
capillaritis can also cause acute ILD leading to acute respiratory
failure, typically with oral anticoagulants, fibrinolytic agents and
platelet glycoprotein inhibitors.
In summary, acute ILD leading to respiratory failure has an
unpredictable onset (from days to years) but rapid development.
Bronchioalveolar lavage is helpful in diagnosis, while biopsy can
generally be avoided, as it does not always provide a specific
diagnosis. Steroid therapy is useful and the overall prognosis is
favourable, except in the case of DAD.
‘Classic’ drug-associated ILD
Hypersensitivity pneumonitis is probably the most commonly
described pattern of ‘classic’ drug-associated ILD. ‘Allergic’ or
‘immunological reaction’ of the lung has also been used instead of
‘hypersensitivity pneumonitis’, as hypersensitivity pneumonitis
can be considered as only the result of inhaled materials. It is not
Table 1 Acute and ‘classic’ drug-associated ILD
Drug-associated acute ILD with acute respiratory failure ‘Classic’ drug-associated ILD
Methotrexate lung Hypersensitivity pneumonitis
K Typical drugs: methotrexate, chrysotherapy (gold) K Typical drugs: methotrexate, chrysotherapy, cyclophosphamide, nitrofurantoin,
antidepressants
K Characteristic features: lymphocytic BAL fluid, history of infiltrative lung disease,
high fever
K Characteristic features: sensitisation, lymphocytic BAL fluid
K Diagnosis: BAL, biopsy K Diagnosis: histopathology, BAL
K Outcome: favourable, usually recovers with steroids or on dechallenge K Outcome: favourable, usually recovers with steroids or on dechallenge
Acute EP
K Typical drugs: minocycline K Typical drugs: methotrexate, sulphasalazine, minocycline, para-aminosalicyclic
acid, nitrofurantoin, nonsteroidal anti-inflammatory drugs
K Characteristic features: eosinophilic BAL fluid, fever, skin rash K Characteristic features: eosinophilic BAL fluid, skin rash, fever, ‘photographic
negative of pulmonary oedema’ on radiography
K Diagnosis: BAL K Diagnosis: BAL
K Outcome: favourable on cessation of minocycline K Outcome: favourable, usually recovers with steroids or on dechallenge
Chemotherapy lung with DAD Amiodarone pneumonitis
K Typical drugs: bleomycin, busulfan, carmustine, mitomycin K Typical drugs: amiodarone
K Characteristic features: DAD K Characteristic features: dyspnoea, chest pain, cough, mild fever, asymmetrical
nonsegmental opacities on radiography
K Diagnosis: radiography, HRCT K Diagnosis: radiography
K Outcome: death in 50–60% of patients K Outcome: favourable
Pulmonary oedema Pulmonary fibrosis
K Typical drugs: ARA-C, B2R-agonists, blood, blood products, narcotics, diuretics K Typical drugs: amiodarone, chemotherapy
K Characteristic features: permeability leakage in alveoli, bilateral consolidation on
radiography
K Characteristic features: fibrotic nonspecific interstitial pneumonia
K Diagnosis: water in BAL fluid K Diagnosis: radiography
K Outcome: favourable K Outcome: poor
Alveolar haemorrhage Desquamative interstitial pneumonia
K Typical drugs: oral anticoagulants, fibrinolytic agents, platelet glycoprotein
inhibitors
K Typical drugs: methotrexate, interferons, etanercept-D2E7
K Characteristic features: bland haemorrhage or capillaritis, diffuse GGA on
radiography
K Characteristic features: alveolar accumulation of macrophages, mosaic pattern
radiograph
K Diagnosis: BAL K Diagnosis: radiography
K Outcome: favourable K Outcome: favourable
ILD¼interstitial lung disease; BAL¼bronchioalveolar lavage; EP¼eosinophilic pneumonia; DAD¼diffuse alveolar damage; HRCT¼high-resolution computed tomography;
GGA¼ground-glass attenuation.
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from therapy with a number of drugs, including methotrexate,
cyclophosphamide, nitrofurantoin and antidepressants (Gonzalez-
Rothi et al, 1995). Hypersensitivity pneumonitis has a granulo-
matous pathology, characterised as an immunologically induced
disorder resulting from sensitisation.
Acute and chronic forms of EP are well recognised as
manifestations of drug-associated ILD. Mild drug-associated ILD
EP is most commonly observed in association with methotrexate,
sulphasalazine, para-aminosalicylic acid, nitrofurantoin and non-
steroidal anti-inflammatory drugs. Eosinophilic pneumonia is
characterised histologically by the accumulation of eosinophils in
the alveolar airspaces, with infiltration of the adjacent interstitial
space by eosinophils and variable numbers of lymphocytes and
plasma cells. Chest radiography and HRCT demonstrate bilateral
airspace consolidation, which tends to involve mainly the
peripheral lung regions and the upper lobes.
Short-term (10 days) and long-term (14 years) therapy with
amiodarone can lead to dose-related pneumonitis, with onset
being acute, rapid, progressive or delayed. Radiographic images,
although variable, are invaluable in diagnosis. In addition,
gradual-onset pulmonary fibrosis, although rare, can develop
following therapy with amiodarone, chemotherapy or radio-
therapy. Furthermore, additional unusual patterns of drug-
associated ILD such as granuloma can be observed following
methotrexate, interferon or bacillus Calmette–Guerin therapy.
There are several patterns of ILD other than ILD with acute
respiratory failure and ‘classic’ ILD. Exogenous lipoid pneumonia
is an uncommon condition resulting from aspirating or inhaling
lipoid material found in laxatives or various aerosolised industrial
materials (Spickard III and Hirschmann, 1994). These substances
produce a foreign-body reaction and proliferate fibrosis in the
lung. Diagnosis is easily reached by examination of sputum, which
demonstrates lipidotic macrophages. Early discontinuation of
exposure leads to lung function improvement before any serious
complications have chance to develop.
Drug-associated BOOP can occur following treatment with
amiodarone, interferon, mesalazine, bleomycin, gold, nilutamide
or penicillamine. Bronchiolitis obliterans organising pneumonia is
a chronic inflammatory process, predominantly involving the
respiratory bronchioles and alveolar ducts. It is characterised by
lipid-laden macrophages in the distal airspaces and focal plugs of
immature fibroblasts (Masson bodies) within the airways. Prog-
nosis is favourable, although drug withdrawal is essential.
Additionally, multiple lung nodules are observed with bleomycin,
amiodarone and minocycline therapy. These lung nodules mimic
metastases and are generally poorly defined.
RECENT EXPERIENCE OF DRUG-ASSOCIATED ILD IN
JAPAN
A considerable proportion of the available literature on ILD, both
general and drug associated, comes from Japan. Explanations
include the possibility that ILD may be more prevalent among the
Japanese or that a greater awareness of the disease could lead to
more frequent diagnosis. For example, there is comprehensive
prescribing information for chemotherapeutic agents with a higher
degree of concern regarding ILD. This may account for the more
frequent reports of chemotherapy-associated ILD in Japan than
elsewhere in the world. Alternatively, there may be a specific
increased genetic susceptibility to ILD among the Japanese
population.
ILD associated with conventional NSCLC chemotherapy
Current guidelines recommend the use of platinum-based
combination chemotherapy for patients with advanced lung cancer
combined with radiotherapy, depending on the stage of disease
(ESMO, 2003). In the USA and Japan, the most frequently used
protocol is carboplatin and paclitaxel, while in Europe it is
cisplatin and gemcitabine.
The literature includes a number of reports of ILD thought to be
associated with lung cancer chemotherapy, such as gemcitabine
(Lilly, 2003), docetaxel (Kunitoh et al, 1996; Merad et al, 1997;
Wang et al, 2001), paclitaxel, irinotecan and vinorelbine (Erasmus
et al, 2002). Treatment of NSCLC with combination chemora-
diotherapy has also been associated with the development of ILD
(Aviram et al, 2001). Increases in drug dose and combinations of
different drugs, and sequential use of radiotherapy and che-
motherapy, increase the incidence of ILD.
In recent years, interstitial pneumonia has been described in
Japan as an important adverse event of new chemotherapy drugs
such as paclitaxel, docetaxel and gemcitabine.
Experience with novel lung cancer treatments
In clinical trials of gefitinib, an epidermal growth factor receptor
tyrosine kinase inhibitor, B40% of patients with advanced NSCLC
Figure 1 BAL of patients with drug-associated acute ILD. (A)
Lymphocytes present in BAL fluid as observed, for example, in cases of
‘methotrexate lung’. (B) Eosinophils present in BAL fluid as observed in EP
due to, for example, minocycline treatment.
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demonstrated clinical benefit of response/disease stabilisation
accompanied by a rapid improvement of symptoms (Fukuoka et al,
2003; Kris et al, 2003). This represents unprecedented disease
control and symptom improvement in this disease setting. Despite
an absence of pulmonary complications in preclinical evaluations
and no obvious imbalance in pulmonary complications/ILD in the
gefitinib and placebo arms of INTACT (‘Iressa’ NSCLC Trial
Assessing Combination Therapy) 1 and 2 (Forsythe and Faulkner,
2003a), a significant number of reports of patients developing ILD
surfaced shortly after the introduction of gefitinib in Japan. It
recently became apparent that the reporting rate of gefitinib-
associated ILD is higher in Japan than in the rest of the world,
although overall the balance of clinical benefit with gefitinib
outweighs the risk of ILD.
In 492000 patients worldwide, who have received gefitinib, the
reported incidence of ILD is B1%; outside Japan, in a global
compassionate-use programme involving 439000 patients, the
reported incidence is B0.3% (Forsythe and Faulkner, 2003b). In
Japan, 39000 patients have received gefitinib therapy and the
reported incidence of ILD is around 1.9% (Table 2) (Forsythe and
Faulkner, 2003b). Reasons for the difference in incidence between
Japan and the rest of the world are unknown and require further
scientific investigation. Interstitial lung disease has also been
observed in patients who have received treatment with the
epidermal growth factor receptor tyrosine kinase inhibitor
erlotinib (Yamamoto et al, 2003).
The disparity of ILD reporting rates in Japanese patients with
NSCLC compared with those in the rest of the world has raised
some important questions involving epidemiology, disease me-
chanisms, disease comorbidity and methods of diagnosis. How-
ever, the demographic characteristics of gefitinib-treated patients
with ILD reflected the characteristics of the overall patient
population, and there was no obvious pattern to the ILD events
with respect to time of onset, age, gender or previous treatments.
Similarly, the comorbidities and previous/concurrent medications
of patients treated post approval in Japan are similar to those of
patients treated outside Japan on a compassionate-use basis as
part of an Expanded Access Programme.
Pathology of gefitinib-associated ILD
In a series of eight patients who underwent autopsy following
death from acute lung injury associated with the use of gefitinib,
the pathological diagnosis of DAD was made (AstraZeneca and
Iressa Expert Committee, 2003) (Figure 2). Pre-existing ILD,
including usual interstitial pneumonia, was found in three of the
eight patients.
Idiopathic pulmonary fibrosis as a prognostic risk factor
for ILD associated with gefitinib
Clinical examination of the total population of 152 patients with
ILD suggested that the presence of idiopathic pulmonary fibrosis
(IPF) affected outcome from ILD (for an analysis of maximum
likelihood estimates, P¼0.048). There was pre-existing IPF in 23
out of 48 patients. For a group of 29 out of 152 patients for whom
CT scans were available before and after onset of ILD, 12 had pre-
existing IPF and 7 (58%) died; 17 did not have pre-existing IPF and
only 3 (18%) of these patients died. Hence, the presence of IPF
seems to be an important risk factor.
Radiology of gefitinib-associated ILD
Clinical examinations of 152 patients with ILD were performed. In
a series of 47 patients from this population for whom HRCT was
available, the characteristic images of gefitinib-associated ILD were
of patchy diffuse ground-glass shadows; these HRCT images were
similar to those of drug-associated lung injury (AstraZeneca and
Iressa Expert Committee, 2003). Several characteristic HRCT
patterns that are seen in other drug-associated ILDs were also
observed in the gefitinb-associated condition (e.g. acute interstitial
pneumonia-like pattern, cryptogenic organised pneumonia-like
pattern, EP-like pattern and localised infiltration pattern)
(Figure 3).
Table 2 Incidence of ILD in gefitinib-treated patients (Forsythe and
Faulkner, 2003b)
Gefitinib-treated patients Incidence of ILD (death), %
Globally (n¼B92750) 0.99 (0.36)
Japan marketed use (n¼B39600) 1.86 (0.69)
Outside Japan (n¼B53150) 0.34 (0.11)
US EAP (n ¼B24200) 0.39 (0.08)
Rest of world EAP (n¼B15000) 0.38 (0.21)
EAP¼expanded access programme; ILD¼interstitial lung disease.
Figure 2 Pathology of gefitinib-associated ILD (AstraZeneca and Iressa Expert Committee, 2003).
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USE OF GEFITINIB
Case histories of four Japanese patients with NSCLC treated with
gefitinib, who developed interstitial pneumonia during treatment
at the Institute of Development Aging and Cancer, Tohoku
University, Sendai, illustrate some of the clinical patterns and
presentation of ILD in patients treated with gefitinib (Inoue et al,
2003). We present these case histories in greater detail here.
First case
The first case described is that of a 69-year-old male smoker
(15 pack-years) with stage IV bronchioalveolar carcinoma who had
undergone three courses of chemotherapy. After 2 weeks’ gefitinib
treatment, an apparent reduction in the alveolar consolidation by
bronchioalveolar carcinoma on HRCT scan was observed. How-
ever, on day 11 of gefitinib therapy, abrupt onset of high fever and
subsequent dyspnoea was noted. New ground-glass attenuation
(GGA) appeared in both sides of the upper lobes on HRCT scan.
Serum levels of SP-D, KL-6, CRP and LDH were elevated. Serum
SP-D and KL-6 are useful markers for alveolar damage in ILD.
Drug-associated interstitial pneumonitis was suspected and
gefitinib therapy was continued for a further 2 months with
concurrent administration of corticosteroids. By day 30, respira-
tory status was improved and the GGA of the upper lobes on
HRCT scan was diminished. Gefitinib therapy ceased and
corticosteroid therapy was continued for approximately 1 month
until death due to bronchioalveolar carcinoma. At autopsy, there
were no apparent lesions with DAD or evidence of acute lung
injury and no infection was found.
Second case
The second case described is that of an 85-year-old male smoker
(50 pack-years) with squamous cell carcinoma of the lung. After
radiotherapy (60Gy), serum levels of both SP-D and KL-6 were
gradually increased and GGA with reticular shadows was noted on
HRCT scan, suggesting the onset of radiation pneumonitis.
Furthermore, tumour size gradually increased after radiotherapy.
Gefitinib therapy was started, but was discontinued on day 18
when sudden-onset anorexia and dyspnoea were noted. On day 20,
acute lung injury was suspected due to acute onset of severe
hypoxia and the bilateral diffuse distribution of GGA on HRCT
scan. Death occurred 2 days later, in spite of high-dose steroid
therapy.
At autopsy, squamous cell carcinoma tumours contained central
necrosis and fibrosis, suggesting the effects of radiation and
gefitinib therapy. Diffuse alveolar damage distributed chiefly on
the right lung demonstrated marked congestion and oedema. The
lesions with organising pneumonia were also densely distributed.
Third case
The third case described is that of a 61-year-old male smoker
(12 pack-years) with well-differentiated adenocarcinoma who had
undergone right lower lobectomy 5 years previously and in whom
metastases were noted in the left lung 2 years later. For 2 years
various chemotherapy was administered but the tumour gradually
enlarged.
Gefitinib therapy was started and continued for 83 days before
being discontinued due to tumour progression. Treatment with
gefitinib was restarted after 3 months along with one administra-
tion of docetaxel (60mgm
 2) after 11 days of gefitinib. At 19 days
after gefitinib treatment was restarted, high fever, dyspnoea,
hypoxemia and elevated serum levels of SP-D, KL-6 and CRP were
observed. Antibiotic therapy was not effective and, due to bilateral
GGA on HRCT scan and high SP-D and KL-6 levels, drug-
associated pneumonitis was strongly suspected. After high-dose
steroid therapy, symptoms and GGA on HRCT were remarkably
improved.
Figure 3 Radiology of gefitinib-associated ILD. (A) Acute interstitial pneumonia-like observations. (B) Chronic organised pneumonia-like observations.
(C) Acute EP-like observations. (D) Light ground-glass shadows in bilateral lung fields lacking shrinkage of lung field and traction bronchiectasis (AstraZeneca
and Iressa Expert Committee, 2003).
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The fourth case described is that of a 78-year-old male smoker
(63 pack-years) with stage IIIb large cell carcinoma who had
undergone radiotherapy (66Gy). Ground-glass attenuation noted on
HRCT scan suggested radiation pneumonitis and steroid therapy
was started. Treatment with gefitinib was stared while the patient
was still receiving steroid treatment. On day 4 of gefitinib therapy,
dyspnoea was noted and gefitinib was discontinued. Serum levels of
CRP, SP-D and KL-6 were markedly elevated and gefitinib-
associated ILD was suspected. Dyspnoea deteriorated in spite of
high-dose steroid therapy, with abrupt increase of GGA on both
sides of the lung; death occurred 5 days later.
At autopsy, a squamous cell carcinoma showing coagulation
necrosis and haemorrhage in the lower lobe of the right lung was
observed along with DAD showing hyaline membranes incorporated
to collapse fibrosis with honeycomb appearance. Granulations
similar to the organising pneumonia pattern and bronchopneumo-
nia were also scattered. Immunohistochemistry demonstrated a
limited number of the epithelial cells infected by cytomegalovirus.
SUMMARY
Drug-associated ILD is common, with diverse patterns ranging
from benign infiltrates to life-threatening acute respiratory distress
syndrome. An accurate diagnosis of drug-associated ILD is based
on clinical, radiological and histological manifestations. However,
diagnosis is often only possible by exclusion. While ILD should be
monitored carefully in NSCLC, the context of the overall toxicity
profile of the treatment and the serious nature of the disease
should be considered alongside the efficacy of the agents
concerned. Standard chemotherapy regimens are associated with
a degree of toxicity and toxicity-related death (Schiller et al, 2002)
and, furthermore, patients with advanced NSCLC have a very poor
prognosis, with few treatment options, and ILD is a comorbid
disease of lung cancer. Gefitinib is an example of a new targeted
therapy for the treatment of lung cancer that has demonstrated
unprecedented activity in pretreated patients and is not associated
with the burden of toxicity of chemotherapy. Cases of ILD have
been reported in Japan for patients treated with gefitinib, with
an overall incidence higher than that observed in the rest of the
world. Although vigilance for pulmonary toxicity is mandatory,
overall, the balance of clinical benefit with gefitinib outweighs the
risk of ILD.
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